MENU
HLN
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

HLN stock forecast, quote, news & analysis

Haleon is one of the largest consumer health companies in the world... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
HLN
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for HLN with price predictions
Oct 27, 2026

HLN in -1.85% downward trend, declining for three consecutive days on October 27, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HLN declined for three days, in 117 of 220 cases, the price declined further within the following month. The odds of a continued downward trend are 53%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HLN moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 12 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 43%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

HLN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HLN entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on HLN as a result. In 41 of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.

The Moving Average Convergence Divergence (MACD) for HLN just turned positive on October 08, 2026. Looking at past instances where HLN's MACD turned positive, the stock continued to rise in 20 of 35 cases over the following month. The odds of a continued upward trend are 57%.

HLN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HLN crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 40%.

Following a +0.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where HLN advanced for three days, in 138 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 53%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. HLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.706) is normal, around the industry mean (8.432). P/E Ratio (27.541) is within average values for comparable stocks, (-1.821). Projected Growth (PEG Ratio) (2.158) is also within normal values, averaging (2.152). Dividend Yield (0.025) settles around the average of (0.044) among similar stocks. P/S Ratio (2.739) is also within normal values, averaging (178.797).

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

A.I.Advisor
published Dividends

HLN paid dividends on September 17, 2026

Haleon plc HLN Stock Dividends
А dividend of $0.06 per share was paid with a record date of September 17, 2026, and an ex-dividend date of August 14, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.33B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -2%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 7%. LQDA experienced the highest price growth at 25%, while SXTC experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -20%. For the same stocks of the Industry, the average monthly volume growth was -33% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 59
Price Growth Rating: 60
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 0 (-100 ... +100)
HLN in -1.85% downward trend, declining for three consecutive days on October 27, 2026